Logo image of TXMD

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

NASDAQ:TXMD - Nasdaq - US88338N2062 - Common Stock - Currency: USD

1.11  -0.01 (-0.89%)

Fundamental Rating

3

Overall TXMD gets a fundamental rating of 3 out of 10. We evaluated TXMD against 194 industry peers in the Pharmaceuticals industry. The financial health of TXMD is average, but there are quite some concerns on its profitability. TXMD has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TXMD had negative earnings in the past year.
In the past year TXMD had a positive cash flow from operations.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD reported 4 times negative operating cash flow.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

TXMD has a Return On Assets of -5.49%. This is in the better half of the industry: TXMD outperforms 74.23% of its industry peers.
TXMD's Return On Equity of -7.85% is fine compared to the rest of the industry. TXMD outperforms 78.35% of its industry peers.
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROIC N/A
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

TXMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXMD remains at a similar level compared to 1 year ago.
TXMD has more shares outstanding than it did 5 years ago.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -34.18, we must say that TXMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.18, TXMD is doing worse than 86.60% of the companies in the same industry.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -34.18
ROIC/WACCN/A
WACC9.74%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TXMD has a Current Ratio of 2.64. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TXMD (2.64) is comparable to the rest of the industry.
A Quick Ratio of 2.64 indicates that TXMD has no problem at all paying its short term obligations.
TXMD's Quick ratio of 2.64 is in line compared to the rest of the industry. TXMD outperforms 50.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.64
Quick Ratio 2.64
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

TXMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.12%, which is quite impressive.
Looking at the last year, TXMD shows a very strong growth in Revenue. The Revenue has grown by 52.78%.
The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%

3.2 Future

The Earnings Per Share is expected to decrease by -8.87% on average over the next years.
Based on estimates for the next years, TXMD will show a small growth in Revenue. The Revenue will grow by 1.92% on average per year.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 6.40, the valuation of TXMD can be described as very cheap.
Based on the Price/Forward Earnings ratio, TXMD is valued cheaper than 92.27% of the companies in the same industry.
TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 6.4
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TXMD is valued cheaply inside the industry as 91.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.13
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

A cheap valuation may be justified as TXMD's earnings are expected to decrease with -18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAPEUTICSMD INC

NASDAQ:TXMD (8/1/2025, 8:07:54 PM)

1.11

-0.01 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-11 2025-08-11
Inst Owners44.06%
Inst Owner Change0%
Ins Owners1.55%
Ins Owner Change0.18%
Market Cap12.84M
Analysts43.33
Price TargetN/A
Short Float %0.16%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.4
P/S 6.98
P/FCF 9.13
P/OCF 9.13
P/B 0.48
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)0.17
Fwd EY15.62%
FCF(TTM)0.12
FCFY10.96%
OCF(TTM)0.12
OCFY10.96%
SpS0.16
BVpS2.31
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 76.43%
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.64
Quick Ratio 2.64
Altman-Z -34.18
F-Score7
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y55.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y117.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.2%
OCF growth 3YN/A
OCF growth 5YN/A